Article Details
Retrieved on: 2025-05-16 14:31:38
Tags for this article:
Click the tags to see associated articles and topics
Summary
The article explains Emrelis' FDA approval for non-squamous NSCLC with c-Met overexpression, highlighting peripheral edema as a common side effect. This approval links to tags like orphan drugs and antibody-drug conjugates in lung cancer treatment.
Article found on: www.cancertherapyadvisor.com
This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.
Sign UpAlready have an account? Log in here